scholarly journals The management of type 2 diabetes with fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A short-term cost-effectiveness analysis in the UK setting

2018 ◽  
Vol 20 (10) ◽  
pp. 2371-2378 ◽  
Author(s):  
Russell Drummond ◽  
Samuel Malkin ◽  
Michelle Du Preez ◽  
Xin Ying Lee ◽  
Barnaby Hunt
Keyword(s):  
Type 2 Diabetes ◽  
Cost Effectiveness ◽  
Insulin Glargine ◽  
Fixed Ratio ◽  
Insulin Degludec ◽  
Short Term ◽  
Effectiveness Analysis ◽  
The Uk ◽  
Basal Bolus

scholarly journals DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal–Bolus Regimens for Type 2 Diabetes in the UK

2018 ◽  
Vol 9 (3) ◽  
pp. 1217-1232 ◽  
Author(s):  
Richard F. Pollock ◽  
◽  
William J. Valentine ◽  
Steven P. Marso ◽  
Jens Gundgaard ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Glargine ◽  
Cost Utility ◽  
Insulin Degludec ◽  
Short Term ◽  
The Uk ◽  
Basal Bolus

scholarly journals Short-Term Cost-Effectiveness of Switching to Insulin Degludec in Japanese Patients with Type 2 Diabetes Receiving Basal–Bolus Therapy

2019 ◽  
Vol 10 (4) ◽  
pp. 1347-1356
Author(s):  
Jakob Langer ◽  
Michael L. Wolden ◽  
Seiya Shimoda ◽  
Miki Sato ◽  
Eiichi Araki
Keyword(s):  
Type 2 Diabetes ◽  
Cost Effectiveness ◽  
Japanese Patients ◽  
Insulin Degludec ◽  
Short Term ◽  
Basal Bolus

Validation of the pharmacoeconomic model of cost-effectiveness analysis of insulin degludec (Tresiba®) in comparison with the insulin glargine u300 in the treatment of type 2 diabetes mellitus in the Russian Federation

2021 ◽  
Vol 9 (3) ◽  
pp. 11-16
Author(s):  
M.V. Globin ◽  
A.Y. Kulikov ◽  
A.A. Litvinova ◽  
V.G. Serpik
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cost Effectiveness ◽  
Insulin Glargine ◽  
Insulin Degludec ◽  
Effectiveness Analysis ◽  
Pharmacoeconomic Model ◽  
The Russian Federation

The global pharmacoeconomic model of cost-effectiveness analysis of insulin degludec (Tresiba®) use in comparison with insulin glargine U300 in the treatment of type 2 diabetes mellitus, was validated. As the result, it was found that the model is relevant to local clinical practice, fully complies with the pharmacoeconomics methodology, takes into account the entire spectrum of costs relevant for the pharmacoeconomic evaluation of insulin in Russia, and the computations built in it is correct. Based on the actual cost data entered, the model calculated the ICER of degludec insulin, which was 214,714 rubles, which does not exceed the sum of three GDP per capita – 2,184,562 rubles and corresponds to the willingness to pay threshold in the Russian Federation. Thus, the insulin degludec (Tresiba®) can be considered as cost-effective from the standpoint of the conducted pharmacoeconomic analysis.

Sign in / Sign up

Export Citation Format

Share Document